Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience-Reference-Cited by-同舟云学术

Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience

Published:2022-10-12 Issue:1 Volume:64 Page:171-177
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Iriyama Noriyoshi¹^ORCID,Miura Katsuhiro¹^ORCID,Takahashi Hiromichi¹²,Nakagawa Masaru¹,Iizuka Kazuhide¹²,Hamada Takashi¹,Koike Takashi¹,Kurihara Kazuya¹,Endo Toshihide¹,Nakayama Tomohiro²,Hatta Yoshihiro¹,Nakamura Hideki¹

Affiliation:

1. Department of Medicine, Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan

2. Department of Pathology and Microbiology, Division of Laboratory Medicine, Nihon University School of Medicine, Tokyo, Japan

Funder

Japan Blood Products Organization.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2131426

Reference27 articles.

1. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

3. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

4. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine;Reactions Weekly;2024-06-29

2. Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-04-30

3. A Case of Primary Adrenal Insufficiency Triggered by Cytomegalovirus Infection after Obinutuzumab plus Bendamustine Therapy for Follicular Lymphoma;Internal Medicine;2024